Pfizer has decided to withdraw its sickle cell disease therapy, Oxbryta, from all markets where it is approved. The company will also discontinue all studies and access programs related to the treatment. This decision is based on the totality of clinical data, which now shows that the risks associated with using Oxbryta outweigh its benefits.
Pfizer reported an imbalance in vaso-occlusive crises, a complication of sickle cell disease, and “fatal events” that require further assessment. The company will review and investigate the available data and has notified regulatory authorities about its findings.
Oxbryta was approved in the US in 2019 for treating inherited blood disorder sickle cell disease, where red blood cells become sickle or crescent shaped. Despite reporting $92 million in revenues from Oxbryta in the second quarter of this year, Pfizer does not anticipate that the withdrawal will impact its full-year 2024 financial outlook.
Source: https://www.cnbc.com/2024/09/25/pfizer-withdraws-sickle-cell-disease-treatment-from-all-markets.html